Targeting TDP-43 Phase Separation Through Selective RNA-Binding Modulation I propose a novel therapeutic paradigm for ALS-FTD that focuses on **selectively disrupting pathological TDP-43 phase separation while preserving physiological condensate formation**. The key insight is that disease-associated TDP-43 mutations alter the protein's RNA-binding specificity, creating aberrant protein-RNA networks that drive toxic phase transitions. Rather than broadly inhibiting TDP-43 aggregation, we should
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.60
Evidence
0.55
Novelty
0.60
Feasibility
0.00
Impact
0.00
Druggability
0.00
Safety
0.00
Competition
0.00
Data
0.00
Reproducible
0.00
KG Connect
0.50
Score Breakdown
Dimension
Targeting TDP-43 Phase Separat
Mechanistic
0.600
Evidence
0.550
Novelty
0.600
Feasibility
0.000
Impact
0.000
Druggability
0.000
Safety
0.000
Competition
0.000
Data
0.000
Reproducible
0.000
KG Connect
0.500
Evidence
Targeting TDP-43 Phase Separation Through Selective RNA-Bind